LifeScan, Inc. manufactures diagnostic equipment. Health care giant Johnson & Johnson sold LifeScan to private equity firm Platinum Equity for $2.1 billion in 2018. It was acquired by J&J in 1986, and in June 2018, J&J agreed to sell LifeScan to Platinum Equity as part of its strategic exit from the diabetes device market, accepting an offer originally tendered in March 2018. LifeScan, Inc. is a leader in blood glucose monitoring products with 2017 net revenue of approximately $1.5 billion. It is classified as operating in the Surgical & Medical Instrument Manufacturing industry. Try D&B Hoovers Free October 01, 2018. LifeScan is a leader in blood glucose monitoring products with 2017 net revenue of approximately $1.5 billion. Completion of the divestiture should be complete by the end of 2018. About LifeScan, Inc. LifeScan, Inc. is a … It is classified as operating in the Surgical & Medical Instrument Manufacturing industry. All reports are in PDF format. Its net revenue reached an estimated $1.5bn in 2017. The Company offers products such as blood glucose meters, test strips, lancing devices, hospital meters, and linearity test kits. Lifescan's annual revenues are $10-$50 million (see exact revenue data) and has 100-500 employees. LifeScan was a Johnson & Johnson (J&J) company. NEW BRUNSWICK, N.J., March 16, 2018 – Johnson & Johnson (NYSE: JNJ) today announced that it has received a binding offer from Platinum Equity, a leading private investment firm, to acquire its LifeScan business for approximately $2.1 billion, subject to customary adjustments. ... 2018. Recent Reports Lifespan 2019 Annual Report (2020) Past Annual Reports Lifespan 2018 Annual Report (2019) Lifespan 2017 Annual Report (2018) Lifespan 2016 Annual Report (2017) Other Reports Lifespan Community Health Needs Assessments and Implementation Strategies Read community health needs assessments and implementation strategies for Lifespan LOS ANGELES (Oct 1, 2018) – Platinum Equity today announced that its acquisition of Lifescan from Johnson & Johnson (NYSE: JNJ) for approximately $2.1 billion has been completed, with the exception of certain non-U.S. jurisdictions that are each expected to close at a later date, subject to individual country regulatory requirements. Johnson & Johnson acquired LifeScan when it bought Animas Corporation in 2008 and was involved in the development and production of new products, such as OneTouch Ping, an insulin pump connected wirelessly to a blood glucose meter. It also makes insulin delivery pumps through its Animas unit. For over 35 years, LifeScan has had a commitment to improving the quality of life for people with diabetes and the help of OneTouch® brand products.